Políticas Médicas
Las políticas médicas son documentos que definen el reconocimiento de cubierta para tecnologías, procedimientos y tratamientos. Las declaraciones de necesidad médica en las políticas, sobre si una tecnología, procedimiento, tratamiento, suplido, equipo, medicamento u otro servicio mejora el resultado en la salud de la población para la cual dicha tecnología o tratamiento fue diseñado se basan en evidencia científica, estudios clínicos y opiniones profesionales de nuestros proveedores y de las organizaciones médicas reconocidas.
Cada documento desplegado en este sitio Web se provee con propósitos informativos solamente y no es una autorización, explicación de beneficios o un contrato. El recibir beneficios está sujeto a la satisfacción de todos los términos y condiciones de la cubierta. La tecnología médica cambia constantemente y nos reservamos el derecho de revisar y actualizar nuestras políticas periódicamente.
| ID | Título | Última Revisión | Siguiente Revisión | Descripción | Acceso |
|---|---|---|---|---|---|
| 11.003.097 | Gene Expression Profiling For Cutaneous Melanoma | Jun 09, 2025 | Jun 20, 2026 | Laboratory tests have been developed that detect the expression of different genes in pigmented lesions or... | Ver |
| 11.003.098 | Use Of Common Genetic Variants (Single Nucleotide Variants) To Predict Risk Of Nonfamilial Breast Cancer | Nov 12, 2025 | Nov 20, 2026 | Several single nucleotide variants (snvs), which are single base-pair variations in the dna sequence of the... | Ver |
| 11.003.099 | Circulating Tumor Dna For Management Of Non-Small-Cell Lung Cancer (Liquid Biopsy) | Dec 10, 2021 | Policy Archived | ... | Ver |
| 11.003.100 | Dna-Based Testing For Adolescent Idiopathic Scoliosis | Mar 05, 2021 | Policy Archived | Adolescent idiopathic scoliosis (ais) is a disease of unknown etiology that causes mild-to-severe spinal... | Ver |
| 11.003.101 | Genetic Testing For Alpha 1 – Antitrypsin Deficiency | Feb 19, 2025 | Feb 20, 2026 | Alpha1-antitrypsin deficiency (aatd) is an autosomal recessive genetic disorder that results in decreased... | Ver |
| 11.003.102 | Genetic Testing For Neurofibromatosis | Feb 05, 2025 | Feb 20, 2026 | Neurofibromatoses are autosomal dominant genetic disorders associated with tumors of the peripheral and... | Ver |
| 11.003.103 | Gene Therapy For Inherited Retinal Dystrophy | Feb 19, 2025 | Feb 20, 2026 | Inherited retinal dystrophy can be caused by recessive variants in the rpe65 gene. patients with biallelic... | Ver |
| 11.003.104 | Genetic Testing For Lipoprotein(A) Variant(S) As A Decision Aid For Aspirin Treatment | Dec 28, 2021 | Policy Archived | Lipoprotein(a) (lpa) is a lipid-rich particle similar to low-density lipoprotein and has been determined to... | Ver |
| 11.003.105 | Microarray-Based Gene Expression Profile Testing For Multiple Myeloma Risk Stratification | Nov 10, 2025 | Nov 20, 2026 | Multiple myeloma is a genetically complex and invariably fatal disease. a host of well-characterized factors... | Ver |
| 11.003.106 | Genetic Testing For Heterozygous Familial Hypercholesterolemia | Nov 05, 2025 | Nov 20, 2026 | Complete appendix to guidelines available at http://journals.aace.com. endocr pract. apr 02 2017; 23(4):... | Ver |
| 11.003.107 | Genetic Testing For Hereditary Pancreatic Cancer | Mar 03, 2025 | Mar 20, 2026 | Pancreatic cancer is the fourth leading cause of cancer death in the united states, accounting for 8.3% of... | Ver |
| 11.003.108 | Measurement Of Serum Antibodies To Selected Biologic Agent | Dec 18, 2025 | Dec 20, 2026 | Biologic agents used to treat autoimmune diseases include infliximab, adalimumab, vedolizumab, and... | Ver |
| 11.003.109 | Human Leukocyte Antigen Testing For Celiac Disease | Dec 05, 2025 | Dec 20, 2026 | Celiac disease (cd) is currently diagnosed by serology, medical history, and response to a gluten-free diet,... | Ver |
| 11.003.110 | Genetic Testing For Statin-Induced Myopathy | Dec 05, 2025 | Dec 20, 2026 | Hmg-coa reductase inhibitors, or statins, which are widely used to treat hypercholesterolemia, can cause... | Ver |
| 11.003.111 | Next Generation Sequencing For The Assessment Of Measurable Residual Disease | Jan 14, 2026 | Jan 20, 2027 | Measurable residual disease (mrd), also known as minimal residual disease, refers to residual clonal cells in... | Ver |
| 11.003.130 | Acupuncture For Pain Management, Nausea And Vomiting, And Opioid Dependence | Dec 09, 2025 | Dec 20, 2026 | Acupuncture describes a group of procedures intended to stimulate anatomical points with the goal of... | Ver |
| 11.003.131 | Sphenopalatine Ganglion Block For Headache | Dec 05, 2025 | Dec 20, 2026 | Chronic migraine and severe headaches are common conditions and the available treatments are not universally... | Ver |
| 11.003.133 | Serologic Genetic And Molecular Screening For Colorectal Cancer | Jan 20, 2026 | Jan 20, 2027 | ... | Ver |
| 11.003.134 | Molecular Testing For Variants Associated With Hereditary Ovarian Cancer | Sep 02, 2025 | Sep 20, 2026 | It is estimated that approximately 20% of women presenting for assessment for hereditary ovarian cancer (oc)... | Ver |
| 11.003.135 | Germline and Somatic Biomarker Testing (Including Liquid Biopsy) for Targeted Treatment and Immunotherapy in Breast Cancer | Jan 20, 2026 | Jan 20, 2027 | Multiple biomarkers are being evaluated to select treatment with an fda-approved targeted treatments for... | Ver |
